Stage IV Lung Cancer Reached Remission After Severe Nerve Damage and Neck Surgery

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: left cervical lymph nodes

Considered in complete remission after cervical lymph-node surgery, with no clinical or radiological progression 24 months after systemic treatment; alive and back at work 3 years after diagnosis.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Shyreece's Patient Story

Patient Info: Shyreece, Female | Stage IV

Biomarkers: ALK rearrangement / ALK-positive

Metastatic Site: Brain

As of March 2022, Shyreece was a long-term Stage IV ALK-positive lung cancer survivor with later brain metastases, ongoing treatment decisions, and advocacy focused on biomarker testing, trials, and disparities in Black lung cancer care.

The Patient StoryRead more →

Early kidney injury after first-line treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function improved after a short prednisone course, and he later continued cancer care with carboplatin and nab-paclitaxel.

PubMed CentralRead more →

ECMO-Supported Airway Tumor Removal in Stage IIB Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage II

He recovered from the emergency airway procedure and remained on systemic cancer treatment at the last follow-up.

PubMed CentralRead more →

Chemotherapy, immunotherapy, and surgery for lung cancer that spread to the foot

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 20%; no actionable mutations on next-generation sequencing.

She had a significant response after four cycles of chemotherapy and pembrolizumab, and the resected lung nodule contained fibrosis and scar without carcinoma; further systemic treatment and radiation were under consideration.

PubMed CentralRead more →

Strong Response to Pembrolizumab-Based Therapy for Pleomorphic Lung Cancer

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 TPS 90%-100%.

A marked response followed four combination cycles, and maintenance pembrolizumab remained ongoing seven months after treatment began.

PubMed CentralRead more →

Pembrolizumab Controlled Metastatic Pleomorphic Lung Cancer After Chemotherapy Failed

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative; PD-L1 TPS 60%-70%; BRCA2, and TP53 mutations; tumor mutation burden 42 mutations/Mb; no actionable alteration.

Metastatic Site: right adrenal gland; left adrenal gland; bone

Tumor diameter had decreased at 11 months, and pembrolizumab remained ongoing at 12 months.

PubMed CentralRead more →

Lung Cancer Metastases to Both Kidneys Causing Kidney Failure

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: PD-L1 highly expressed

Metastatic Site: brain|bilateral kidneys|lungs

The cancer progressed in both kidneys and lungs despite treatment, causing dialysis-dependent kidney failure. He later developed severe respiratory illness and died 5 days after readmission.

PubMed CentralRead more →

Severe headache during chemotherapy for small-cell lung cancer

Patient Info: Anonymized, Male, 50s

After the regimen change, he completed five chemotherapy cycles, remained free of severe headache, and had improvement in chest pain, cough, and breathing.

PubMed CentralRead more →

A painful scalp metastasis from sarcomatoid lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: No targetable mutations identified; CAM5.2-positive; p63-positive; CD10-positive; vimentin-positive.

Metastatic Site: chest wall and rib; liver; right gluteal region; scalp…

Her disease progressed with a further liver lesion and additional metastatic complications, and systemic treatment was stopped because of severe immune-related toxicity and the absence of targetable mutations.

PubMed CentralRead more →

Low-dose intrapleural therapy relieved a complex malignant pleural effusion

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: EGFR mutation-negative; ALK alteration-negative; ROS1 alteration-negative.

Metastatic Site: pleura; adrenal gland; bone

The lung cancer had progressed after initial chemotherapy, but rescue treatment of the infected loculated pleural effusion drained 2,000 mL, resolved the collection, and improved her breathing and fever.

PubMed CentralRead more →

Extensive-stage small cell lung cancer with acquired haemophilia

Patient Info: Anonymized, Female, 60s

Biomarkers: Synaptophysin weakly positive; Ki-67 greater than 90%.

Her small cell lung cancer remained stable on imaging one month before her death, which followed aseptic meningitis after intravenous immunoglobulin treatment for autoimmune myasthenia gravis.

PubMed CentralRead more →

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed CentralRead more →

Blood Vessel Inflammation After Durvalumab Treatment for Stage III Lung Cancer

Patient Info: Anonymized, Female, 70+ | Stage III

The lung cancer had responded well to chemoradiation and durvalumab, while treatment-related pneumonitis and vasculitis improved with corticosteroids and withdrawal or completion of durvalumab.

PubMed CentralRead more →

Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed CentralRead more →

Small-Cell Lung Cancer First Appeared as Rapidly Worsening Nerve Damage

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-Hu-positive; anti-CV2/CRMP5-positive; anti-SOX1-positive

Despite six cycles of carboplatin and etoposide and intensive treatment for the paraneoplastic neuropathy, her neurological condition progressed; after a thrombocytopenia-related brain haemorrhage, she entered palliative care and died within weeks.

PubMed CentralRead more →

Pleomorphic lung cancer responding to pembrolizumab plus chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >75%; EGFR negative; ROS1 negative; ALK fusion negative

Metastatic Site: right 8th rib, left adrenal gland

His general condition improved as the tumors shrank, and he remained well 7 months after diagnosis with maintenance pembrolizumab planned.

PubMed CentralRead more →

Multifocal stage IIIA lung adenocarcinoma responding to nivolumab

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: CK7-positive; TTF-1-positive; napsin-A-positive; PD-L1 85% positive.

The biopsied lung nodule nearly resolved after four nivolumab cycles, and the remaining pulmonary nodules were stable at 24 months.

PubMed CentralRead more →

More than 10 years living with relapsing extensive-stage small cell lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Chromogranin-positive.

Metastatic Site: pleura; pancreas; left kidney and perinephric region

After five treatment lines and several metastatic relapses over more than 10 years, his latest irinotecan and carboplatin course produced another partial response and he was doing well at the last follow-up.

PubMed CentralRead more →

Small cell lung cancer found through a disabling paraneoplastic neuropathy

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-CRMP5 antibody-positive.

She completed chemotherapy and radiation and entered oncology follow-up, while the disabling sensory and motor neuropathy persisted and rehabilitation continued.

PubMed CentralRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed CentralRead more →

Rapidly Progressive Stage IV Lung Adenocarcinoma With a Miliary Imaging Pattern

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: TTF-1-positive; p40-negative; chromogranin-negative; synaptophysin-negative; EGFR-negative; ALK-negative; ROS1-negative; PD-L1 expression 5%–10%.

The cancer progressed rapidly, and he died approximately four months after diagnosis while being transported to inpatient hospice.

PubMed CentralRead more →

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed CentralRead more →